Ad-hoc-announcement according to § 15 WpHG

WILEX´ second product enters Phase III trial: IND approval from FDA for registration trial with CA9-SCAN

Munich, 12 October 2007 – The Munich-based biopharmaceutical company WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard) has received an Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for a pivotal Phase III trial with the medical product candidate CA9-SCAN.

190 patients suspected of having kidney cancer will be enrolled in approximately 17 study centres in the USA. Patients with a renal mass are scheduled for surgery to remove the affected kidney. These patients will be imaged with CA9-SCAN prior to the surgery to determine whether they have clear cell renal cell cancer. Results are expected to be available at the end of 2008.

Contact
Juliane Giese
Manager Public Relations
WILEX AG
Grillparzerstr. 10
81675 München
Germany
Tel.: +49 (0)89-41 31 38-29
Fax: +49 (0)89-41 31 38-99
Email: investors@wilex.com
Website: http://www.wilex.com

This communication contains certain forward-looking statements, relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.